California Public Employees Retirement System Has $7.80 Million Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NEO. Barclays PLC lifted its position in shares of NeoGenomics by 11.0% during the 3rd quarter. Barclays PLC now owns 137,913 shares of the medical research company’s stock valued at $6,652,000 after acquiring an additional 13,691 shares during the period. CIBC Asset Management Inc acquired a new position in shares of NeoGenomics during the third quarter valued at about $233,000. Teacher Retirement System of Texas boosted its position in shares of NeoGenomics by 36.6% during the 3rd quarter. Teacher Retirement System of Texas now owns 18,417 shares of the medical research company’s stock worth $888,000 after purchasing an additional 4,938 shares in the last quarter. O Shaughnessy Asset Management LLC grew its stake in shares of NeoGenomics by 29.4% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 7,288 shares of the medical research company’s stock valued at $352,000 after buying an additional 1,657 shares during the period. Finally, Eagle Asset Management Inc. increased its position in NeoGenomics by 12.0% in the 3rd quarter. Eagle Asset Management Inc. now owns 1,008,175 shares of the medical research company’s stock valued at $48,634,000 after buying an additional 107,851 shares in the last quarter. 95.03% of the stock is owned by institutional investors and hedge funds.
Shares of NEO stock opened at $8.39 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 7.64 and a current ratio of 7.93. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -26.22 and a beta of 0.86. NeoGenomics, Inc. has a 52-week low of $7.26 and a 52-week high of $54.74. The company has a 50-day simple moving average of $12.45 and a two-hundred day simple moving average of $23.51.
NeoGenomics (NASDAQ:NEO – Get Rating) last announced its earnings results on Wednesday, April 27th. The medical research company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. The firm had revenue of $117.17 million for the quarter, compared to the consensus estimate of $116.44 million. NeoGenomics had a negative return on equity of 6.62% and a negative net margin of 7.33%. The company’s revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.06) EPS. On average, sell-side analysts forecast that NeoGenomics, Inc. will post -0.98 EPS for the current fiscal year.
In other news, CFO William Bonello sold 3,209 shares of the firm’s stock in a transaction on Monday, March 7th. The stock was sold at an average price of $18.29, for a total transaction of $58,692.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.00% of the stock is owned by corporate insiders.
NEO has been the subject of a number of research reports. Zacks Investment Research cut NeoGenomics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th. Benchmark decreased their price target on shares of NeoGenomics from $26.00 to $16.00 in a research note on Tuesday, March 29th. StockNews.com upgraded shares of NeoGenomics to a “sell” rating in a report on Thursday, May 12th. Raymond James reduced their price objective on shares of NeoGenomics from $24.00 to $18.00 and set an “outperform” rating for the company in a report on Monday, April 18th. Finally, Craig Hallum lowered their target price on shares of NeoGenomics from $46.00 to $30.00 in a report on Thursday, February 24th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, NeoGenomics has an average rating of “Hold” and a consensus price target of $24.64.
About NeoGenomics (Get Rating)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.
See Also
- Get a free copy of the StockNews.com research report on NeoGenomics (NEO)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source